



# BRAF *therascreen*<sup>®</sup>

## Targeted Therapy with BRAF V600 Mutation Analysis

The BRAF *therascreen* empowers oncologists by pinpointing the BRAF V600E mutation, prevalent in melanoma and colorectal cancer (CRC). Generally, BRAF V600 mutations are found in approximately 5-15% of CRC cases. This critical genetic insight facilitates personalized treatment plans, particularly in metastatic CRC, where it serves as a beacon for selecting patients for BRAFTOVI (encorafenib) in combination with cetuximab therapy. **Rapid results from our assay are typically available within 48-72 hours.**



### Key Benefits:

- **Rapid Results:** Delivering actionable insights within 48 hours, supporting swift clinical decisions.
- **Minimal Sample Requirement:** Leveraging quantitative methodology for efficient testing.
- **FDA Approved:** Validated rigorously to ensure reliability and accuracy.
- **Aligned with NCCN Guidelines:** Part of a comprehensive approach to oncology care.
- **Clinical Precision:** Designed for metastatic colorectal cancer patients, enhancing treatment selection with BRAFTOVI<sup>®</sup> and Cetuximab (ERBITUX<sup>®</sup>) based on BRAF V600E mutation status.

### Optimizing Patient Outcomes:

The BRAF precision medicine test is customized to an individual's genetic blueprint, holds immense promise for enhancing treatment effectiveness and improving patient outcomes. By harnessing genetic data, healthcare providers can finely tune interventions and therapies to match the distinct genetic traits of each patient, resulting in actionable insights delivered in a matter of days rather than weeks.

Jones RP, Sutton PA, et. al. 2017 Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Br J Cancer. Mar 28;116(7):923-929

For more information, please contact us at: [cs@emeritusdx.com](mailto:cs@emeritusdx.com)

**EmeritusDX**  
Together, We Save Lives

800.959.2846

[www.emeritusdx.com](http://www.emeritusdx.com)

### Clinical Utility

#### FDA Approved

Aligned with NCCN Guidelines  
Rapid Results  
Minimal Sample Requirement

**Personalized Treatment**  
**Precision Medicine**  
**Early Detection**



EDX-BRA 0224